Login / Signup

The Challenges and Opportunities in the Development of MicroRNA Therapeutics: A Multidisciplinary Viewpoint.

Mohammad Yahya MominRavinder Reddy GaddamMadeline KravitzAnisha GuptaAjit Vikram
Published in: Cells (2021)
microRNAs (miRs) are emerging as attractive therapeutic targets because of their small size, specific targetability, and critical role in disease pathogenesis. However, <20 miR targeting molecules have entered clinical trials, and none progressed to phase III. The difficulties in miR target identification, the moderate efficacy of miR inhibitors, cell type-specific delivery, and adverse outcomes have impeded the development of miR therapeutics. These hurdles are rooted in the functional complexity of miR's role in disease and sequence complementarity-dependent/-independent effects in nontarget tissues. The advances in understanding miR's role in disease, the development of efficient miR inhibitors, and innovative delivery approaches have helped resolve some of these hurdles. In this review, we provide a multidisciplinary viewpoint on the challenges and opportunities in the development of miR therapeutics.
Keyphrases
  • cell proliferation
  • long non coding rna
  • long noncoding rna
  • clinical trial
  • small molecule
  • phase iii
  • gene expression
  • open label
  • quality improvement
  • high intensity